You have successfully logged out.

Hello !
Logout

Help prevent and treat diabetic foot ulcers

Diabetic Foot Syndrome (DFS)[1,2]

Diabetic foot syndrome (DFS) is a common complication of diabetes mellitus that affects every fourth patient with diabetes at some point in their lifes. The risk of developing DFS increases with age.

 

One of the consequences is skin breakdown or foot ulceration, known as a Diabetic Foot Ulcer (DFU). This condition includes all changes in the foot resulting from diabetic polyneuropathy as well as diabetic micro and macroangiopathic changes.

Infection in Diabetic Foot Ulcers (DFU)​

Did you know?

  • 19- 0%

    of people with diabetes will develop a DFU during their lifetime.[2]

  • More than

    0%

    of such diabetic foot ulcers become infected.[3]

  • Up to

    0%

    of severely infected DFUs lead to osteomyelitis.[4]

Foot icon with highlighted area on the foot's sole , indicating ulcer location.

Foot icon with a highlighted ulcer and bacteria icons, representing signs of infection.

Foot icon with larger highlighted area and bacteria inset on the bone, indicating moderate infection.

Person icon with a thermometer suggesting severe systemic infection.

Get your free guide to DFU infections


An up-to-date handout guide for treatment and management of diabetic foot ulcer infections, based on the IWGDF/IDSA classification and Dr. Prof. José Luis Lázaro’s clinical experience.

Download here

Askina® Calgitrol® Paste

Askina® Calgitrol® Paste is a sterile primary dressing consisting of an ionic silver alginate matrix in paste form, designed to treat chronic wounds which are infected or at high risk of infection.   The paste form, due to its water content, provides immediate availability of silver ions. Additionally, the ionic exchange with the wound exudate, delivers a sustained release of ionic silver to the wound bed.1   It is supplied sterile in a 15 g tube. The tube has a cannula to aid application of the paste into tunnels, sinuses, and all deep wounds. 2

Askina® Calgitrol® Ag+

Askina® Calgitrol® Ag+ is a wound dressing that combines antimicrobial silver with strengthening cellulose fiber to manage wound infection and high exudate. The dressing promotes healing in a moist environment.  When applied, Askina® Calgitrol® Ag+ responds by forming a gel on contact with wound exudate. The gelling formation traps, locks in and kills the bacteria away from the wound bed. It contains encapsulated nanoparticles of ionic silver encrusted into the strengthening cellulose fiber. The nanoparticles act as a reservoir of ionic silver and are released gradually in contact with wound fluid to kill bacteria and microorganisms within the dressing.Under the supervision of a healthcare professional, Askina® Calgitrol® Ag+ antimicrobial wound dressings may be used for:All agesModerately to heavily exuding woundsChronic wounds, e. g. leg ulcers, pressure ulcers and diabetic ulcersSurgical wounds, e. g. post-operative, wounds left to heal by secondary intent and donor sitesTraumatic wounds, e. g. abrasions and lacerationsPartial thickness burnsIf required, the dressings can be used in conjunction with a suitable moisture-retaining secondary dressing to keep the product in place and/or under compression.

Askina® Carbosorb

Askina® Carbosorb provides a combination of a superabsorbent wound dressing and activated charcoal. Most wounds have a slight odor, and malodor is the most distressing and socially isolating symptom associated with wounds. With Askina® Carbosorb, you can manage excess exudate and malodor at the same time and have therefore more time to care for your patients.Box of 10.

Askina® Sorb

Askina® Sorb dressing is a highly absorbent dressing composed of calcium alginate and sodium carboxymethylcellulose (CMC) fibers. The dressing can absorb large amounts of exudate and form a gel which maintains a moist healing environment. Askina® Sorb is available in sheet and rope forms. Askina® Sorb is indicated for moderately to heavily exuding wounds, such as diabetic foot ulcers, pressure ulcers, leg ulcers, superficial and partial thickness burns, donor sites, post-operative wounds and traumatic wounds.

Askina® DresSil Active

Askina® DresSil Active is a multilayer silicone dressing with border designed to provide active exudate management. Its multilayer structure improves exudate retention and absorption while maintaining the adequate moisture level in the wound1. This may reduce the frequency of dressing changes, thereby saving nursing time and allowing more time to be dedicated to patients and their care2.  Askina® DresSil Active is designed for a wide range of exuding wounds such as:Pressure ulcersLeg and foot ulcersTraumatic wounds (e.g. skin tears)Surgical wounds It can also be used on dry/necrotic wounds in combination with gels. The dressing may also be used as part of a prophylactic therapy to help prevent skin damage, e.g. pressure ulcers.

A man stands next to his doctor, both smile into the camera

Rescue from amputation

Do you know the story of Galo, the man whose foot amputation was avoided by a B. Braun sales rep?

Find out more about how wound management with Prontosan® and Askina® changed the situation.

Read the story

References

  1. Rümenapf G, Morbach S, Rother U, Uhl C, Görtz H, Böckler D, Behrendt CA, Hochlenert D, Engels G, Sigl M; Kommission PAVK und Diabetisches Fußsyndrom der DGG e. V.. Diabetisches Fußsyndrom – Teil 1 : Definition, Pathophysiologie, Diagnostik und Klassifikation [Diabetic foot syndrome-Part 1 : Definition, pathophysiology, diagnostics and classification]. Chirurg. 2021 Jan;92(1):81-94. German. doi: 10.1007/s00104-020-01301-9. PMID: 33170315; PMCID: PMC7819949.
  2. Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. N Engl J Med. 2017 Jun 15;376(24):2367-2375
  3. Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, Edmonds M, Holstein P, Jirkovska A, Mauricio D, Ragnarson Tennvall G, Reike H, Spraul M, Uccioli L,  rbancic V, Van Acker K, van Baal J, van Merode F,  chaper N. High prevalence of ischaemia, infection and  erious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study.  iabetologia. 2007 Jan;50(1):18-25. doi: 10.1007/s00125-006-0491-1. Epub 2006 Nov 9. PMID: 17093942.
  4. Lázaro Martínez JL, García Álvarez Y, Tardáguila-García A, García Morales E. Optimal management of diabetic foot osteomyelitis: challenges and solutions. Diabetes Metab Syndr Obes. 2019 Jun 21;12:947-959. doi: 10.2147/DMSO.S181198. PMID: 31417295; PMCID: PMC6593692.
  5. McDermott K, Fang M, Boulton AJM, Selvin E, Hicks CW. Etiology, Epidemiology, and Disparities in the Burden of Diabetic Foot Ulcers. Diabetes Care. 2023 Jan 1;46(1):209- 221. doi: 10.2337/dci22-0043. PMID: 36548709; PMCID: PMC9797649.
  6. Senneville É, Albalawi Z, van Asten SA, Abbas ZG, Allison G, Aragón-Sánchez J, Embil JM, Lavery LA, Alhasan M, Oz O, Uçkay I, Urbančič-Rovan V, Xu ZR, Peters EJG. IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections (IWGDF/IDSA 2023). Clin Infect Dis. 2023 Oct 2:ciad527.
  7. Based on personal expert opinion by Dr. Prof. José Luis Lázaro, Head of Diabetic Foot Ulcers Unit, Universidad Complutense de Madrid
  8. Malone M, Bjarnsholt T, McBain AJ, James GA, Stoodley P, Leaper D, Tachi M, Schultz G, Swanson T, Wolcott RD. The prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of published data. J Wound Care. 2017 Jan 2;26(1):20-25. doi: 10.12968/jowc.2017.26.1.20. PMID: 28103163​